Masimo (MASI) Cash from Financing Activities (2009 - 2026)
Masimo's (MASI) quarterly Cash from Financing Activities came in at -$70.2 million in Q2 2026, down 49.36% year-on-year from -$138.6 million in Q2 2025, and up 67.29% quarter-over-quarter from -$214.6 million in Q1 2026.
Masimo (MASI) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Masimo's Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$70.2 million for Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 49.36% year-over-year to -$70.2 million in Q2 2026; TTM through Apr 2026 was -$541.3 million, a 269.49% decrease from a year earlier, with the FY2026 full-year figure at -$518.1 million, down 312.5% from the prior year.
- Cash from Financing Activities climbed to -$70.2 million in Q2 2026 per MASI's latest filing, from -$214.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $518.0 million in Q3 2022 and bottomed at -$215.8 million in Q3 2025.
- The 5-year median for Cash from Financing Activities is -$30.6 million (2023), against an average of -$23.7 million.
- Across the five-year window, Cash from Financing Activities surged 101.99% in 2024 and plunged 21560.0% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at -$4.7 million in 2022, then sank by 968.09% to -$50.2 million in 2023, then jumped by 101.99% to $1.0 million in 2024, then plunged by 21680.0% to -$215.8 million in 2025, then jumped by 67.47% to -$70.2 million in 2026.
- Per Business Quant, the three latest MASI Cash from Financing Activities figures stand at -$70.2 million (Q2 2026), -$214.6 million (Q1 2026), and -$215.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Masimo | 9.39 Bn | 9.27 Bn | 250.80 Mn | -70.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 4, 2026 | -70.20 Mn |
| Apr 4, 2026 | -70.20 Mn |
| Jan 3, 2026 | -214.60 Mn |
| Jan 3, 2026 | -214.60 Mn |
| Sep 27, 2025 | -215.80 Mn |
| Sep 27, 2025 | -215.80 Mn |
| Jun 28, 2025 | -40.70 Mn |
| Jun 28, 2025 | -40.70 Mn |
| Mar 29, 2025 | -47.00 Mn |
| Mar 29, 2025 | -47.00 Mn |
| Dec 28, 2024 | 1.00 Mn |
| Dec 28, 2024 | 1.00 Mn |
| Sep 28, 2024 | -9.10 Mn |
| Sep 28, 2024 | -9.10 Mn |
| Jun 29, 2024 | -91.40 Mn |
| Jun 29, 2024 | -91.40 Mn |
| Mar 30, 2024 | -26.10 Mn |
| Mar 30, 2024 | -26.10 Mn |
| Dec 30, 2023 | -50.20 Mn |
| Dec 30, 2023 | -50.20 Mn |